200 related articles for article (PubMed ID: 32698738)
1. Fused and Substituted Pyrimidine Derivatives as Profound Anti-Cancer Agents.
Abbas N; Matada GSP; Dhiwar PS; Patel S; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(7):861-893. PubMed ID: 32698738
[TBL] [Abstract][Full Text] [Related]
2. ZnO Nanoparticles Catalyst in the Synthesis of Bioactive Fused Pyrimidines as Anti-breast Cancer Agents Targeting VEGFR-2.
Dawood DH; Abbas EMH; Farghaly TA; Ali MM; Ibrahim MF
Med Chem; 2019; 15(3):277-286. PubMed ID: 30207239
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of 2,6,7-substituted pyrrolo[2,3-d]pyrimidines as cyclin dependent kinase inhibitor in pancreatic cancer cells.
Shi X; Quan Y; Wang Y; Wang Y; Li Y
Bioorg Med Chem Lett; 2021 Feb; 33():127725. PubMed ID: 33316409
[TBL] [Abstract][Full Text] [Related]
4. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological activity and POM/DFT/docking analyses of annulated pyrano[2,3-d]pyrimidine derivatives: Identification of antibacterial and antitumor pharmacophore sites.
Bhat AR; Dongre RS; Almalki FA; Berredjem M; Aissaoui M; Touzani R; Hadda TB; Akhter MS
Bioorg Chem; 2021 Jan; 106():104480. PubMed ID: 33279245
[TBL] [Abstract][Full Text] [Related]
6. Intrinsic drug potential of oxazolo[5,4-d]pyrimidines and oxazolo[4,5-d]pyrimidines.
Zhirnov VV; Velihina YS; Mitiukhin OP; Brovarets VS
Chem Biol Drug Des; 2021 Oct; 98(4):561-581. PubMed ID: 34148293
[TBL] [Abstract][Full Text] [Related]
7. Application and SARs of Pyrazolo[1,5-a]pyrimidine as Antitumor Agents Scaffold.
Zhang Y; Wen D; Shen J; Tian L; Zhu Y; Zhang J; Zhao L; Ding S; Liu J; Chen Y
Curr Top Med Chem; 2023; 23(12):1043-1064. PubMed ID: 36852801
[TBL] [Abstract][Full Text] [Related]
8. Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery.
Li W; Zhang J; Wang M; Dong R; Zhou X; Zheng X; Sun L
Curr Top Med Chem; 2022 Mar; 22(4):284-304. PubMed ID: 35021973
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, biological evaluation and molecular modeling study of new thieno[2,3-d]pyrimidines with anti-proliferative activity on pancreatic cancer cell lines.
Salem MSH; Abdel Aziz YM; Elgawish MS; Said MM; Abouzid KAM
Bioorg Chem; 2020 Jan; 94():103472. PubMed ID: 31813475
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis and Anti-Proliferative Activities of 2,6-Substituted Thieno[3,2-d]pyrimidine Derivatives Containing Electrophilic Warheads.
Zhang Q; Hu Z; Shen Q; Chen Y; Lu W
Molecules; 2017 May; 22(5):. PubMed ID: 28498316
[TBL] [Abstract][Full Text] [Related]
11. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
12. Induction of intrinsic apoptosis pathway in colon cancer HCT-116 cells by novel 2-substituted-5,6,7,8-tetrahydronaphthalene derivatives.
Gamal-Eldeen AM; Hamdy NA; Abdel-Aziz HA; El-Hussieny EA; Fakhr IM
Eur J Med Chem; 2014 Apr; 77():323-33. PubMed ID: 24657569
[TBL] [Abstract][Full Text] [Related]
13. FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
Wang S; Yuan XH; Wang SQ; Zhao W; Chen XB; Yu B
Eur J Med Chem; 2021 Mar; 214():113218. PubMed ID: 33540357
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
15. An appraisal on synthetic and pharmaceutical perspectives of pyrazolo[4,3-d]pyrimidine scaffold.
Cherukupalli S; Hampannavar GA; Chinnam S; Chandrasekaran B; Sayyad N; Kayamba F; Reddy Aleti R; Karpoormath R
Bioorg Med Chem; 2018 Jan; 26(2):309-339. PubMed ID: 29273417
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and in vitro biological evaluation of novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives containing a thiosemicarbazide moiety.
Geng PF; Liu XQ; Zhao TQ; Wang CC; Li ZH; Zhang J; Wei HM; Hu B; Ma LY; Liu HM
Eur J Med Chem; 2018 Feb; 146():147-156. PubMed ID: 29407946
[TBL] [Abstract][Full Text] [Related]
17. Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.
Ali EMH; Abdel-Maksoud MS; Oh CH
Bioorg Med Chem; 2019 Apr; 27(7):1159-1194. PubMed ID: 30826188
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel substituted pyrimidine derivatives bearing a sulfamide group and their in vitro cancer growth inhibition activity.
Lefebvre CA; Forcellini E; Boutin S; Côté MF; C-Gaudreault R; Mathieu P; Lagüe P; Paquin JF
Bioorg Med Chem Lett; 2017 Jan; 27(2):299-302. PubMed ID: 27903409
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrazolo[3,4-d]pyrimidine derivatives inhibit human cancer cell proliferation and induce apoptosis by ROS generation.
Gaonkar S; Savanur MA; Nadaf AA; Najare MS; Mantur S; Garbhagudi M; Mulla SI; Khazi IAM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900296. PubMed ID: 32073686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
